Keynote Address

Keynote Address: Mechanisms and Functional Disruption of Immuno-Evasive Barriers in the Tumor Microenvironment
Douglas Hanahan, PhD – Ludwig Institute for Cancer Research, Lausanne Branch/Swiss Federal Institute of Technology Lausanne (EPFL)/Swiss Cancer Center Leman (SCCL)

Session I: Novel Insights to the TME in IO Response

Tumor Microenvironment
Marcia Haigis, PhD - Harvard Medical School

(87) The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer

Rahul Shinde, DVM, PhD – The Wistar Institute

(79) Spatial analysis of local drug induced changes in tumor microenvironment predicts effective treatment combinations in breast cancer 

Zuzana Tatarova, PhD – Brigham and Women's Hospital

Abstract Q&A

Session II: Aging and Sex Hormones and Other Factors that Influence Immunotherapy Response

Androgens and Immunotherapy: Rethinking Mechanisms of Resistance in Hormone-Dependent Cancers
Amy Moran, PhD – Oregon Health & Science University

Sexual Dimorphism of the Aging Tumor Microenvironment Dictates Melanoma Growth and Therapeutic Responses
Yash Chhabra, PhD – Johns Hopkins

(13) Estrogen signaling via estrogen receptors alpha and beta impacts the function of Foxp3+ T-regulatory cells

Lanette Christensen, PhD – Children's Hospital of Philadelphia

(72) Sex-biased Yap1 function in immune suppression

Kyuson Yun, PhD – Houston Methodist/Well Cornell Med

Session III: Cutting Edge Clinical Trials with Novel Immunotherapy Targets

Targeting the Microbiome to Overcome Resistance to Immune Checkpoint Blockade
Nazli Dizman, MD – Yale School of Medicine

(46) Flt3L-primed in Situ Vaccination and pembrolizumab induce systemic tumor regressions of non-immunotherapy responsive tumors

Thomas Marron, MD, PhD – Icahn School of Medicine at Mount Sinai

(73) Clinical and correlative results from a trial of in situ cancer vaccination in lymphoma

Tanaya Shree, MD, PhD – Oregon Health & Sciences University

Workshop: Integrating Spatial-Omics in IO/Single Cell Analysis

Establishing Causality of Spatial Relationships
Brian Brown, PhD – Mount Sinai Medical Center

Image Analysis of Immune Contexture 

Kenneth Hu, PhD – University of California San Francisco

From Images to Single-cell Data: A Primer on Multiplex Tissue Analysis
Gregory J. Baker, PhD, PharmD – Harvard University

Application of MERFISH Spatial Transcriptomics to Understanding Immunotherapy Responsive Tumors 

Pauline Hamon, PhD – Icahn School of Medicine at Mount Sinai

Panel Discussion

Session IV: Impact of Gut, Tumor and Other Microbes on Cancer Development and Therapy Response

Co-Chairs:
Abigail Overacre-Delgoffe, PhD – University of Pittsburgh
Laurence Zitvogel, MD, PhD – Institute Gustave Roussy

Microbiome-Immune Interactions in Cancer

Abigail Overacre-Delgoffe, PhD – University of Pittsburgh

(11) Bacteria specific IL-10 secreting T-cells derived from the gut are cross-reactive with tumor antigens and accelerate tumor growth in mouse models

Denise Cecil, PhD – University of Washington

(49) Distinct microbial communities play a role in metastatic brain tumors

Golnaz Morad, DDS, PhD – The University of Texas MD Anderson Cancer Center

Session V: Immune-Related Toxicity and COVID

Chair:
E. John Wherry, PhD – University of Pennsylvania

T Cells Specific for α-myosin Drive Immunotherapy-Related Myocarditis
Justin Balko, PhD, Pharm D – Vanderbilt University Medical Center

Use of ‘Analytical Vaccination’ to Predict Immune Related Adverse Events to Checkpoint Blockade

E. John Wherry, PhD – University of Pennsylvania

(37) Immunotoxicology analysis of IL-12ns reveals biomarkers of beneficial and maladaptive immune responses in healthy BALB/c mice

Ryan Lacinski, BS – West Virginia University School of Medicine

(57) Treatment with metronidazole improves response and reduces toxicity to treatment with immune checkpoint blockade

Elizabeth Park, PhD – The University of Texas MD Anderson Cancer Center 

Session VI: Novel Insights into Adoptive Cell Therapy

Co-Chairs:
Francesco Marincola, MD – Kite, A Gilead Company
Avery Posey, PhD – University of Pennsylvania Perelman School of Medicine

Opening Remarks

(5) Lung cancer-associated myeloid cells dictate the immunologic response to oncolytic adenovirus

Svetlana Atasheva, PhD – Emory University

(23) Redirecting in vitro glucose flux improves the in vivo anti-tumor function of cellular immunotherapies

Andrew Frisch, BS – University of Pittsburgh

Workshop: Career Development Across the Continuum: Building and Using a Network to Shape Your Career 

Path of Career Development – Academia to Pharma
Zac Cooper, PhD – AstraZeneca

Building Bridges and Creating Networks
Gordon Mills, MD, PhD – Oregon Health & Science University

Funding and Maintaining Funding of Your Lab (grants, partnerships)
Ashani Weeraratna, PhD – Johns Hopkins

What Journals Look for in a Manuscript
James Gulley, MD, PhD, FACP – National Cancer Institute

What Journals Look for in a Manuscript

Bailee Sliker, PhD – Cancer Discovery

Breakout Tables
Table 1: Grants
Table 2: Career Development - Academia
Table 3: Career Development - Pharma
Table 4: Manuscripts

Session VII: Pre-Cancer Interception/Prevention

Co-Chairs:
Shawn Demehri, MD, PhD – Massachusetts General Hospital
Eduardo Vilar-Sanchez, MD, PhD – The University of Texas MD Anderson Cancer Center

Cancer Immune Interception in Lynch Syndrome

Eduardo Vilar-Sanchez, MD, PhD – The University of Texas MD Anderson Cancer Center

Antigen Identification and Preventive Vaccine Development for Pre-Malignant Breast Lesions 

Sasha Stanton, MD, PhD – Providence Cancer Institute/ Earle Chiles Cancer Research Institute

Session VIII: Insights from Non-Tumor Sites in IO Response

Co-Chair:
Matt Spitzer, PhD – University of California, San Francisco

(65) Lymph node colonization promotes distant tumor metastasis through the induction of tumor-specific immune tolerance

Nathan Reticker-Flynn, PhD – Stanford University

(80) TLT-1, a platelet released protein, suppresses CD8 T cell based systemic immunity, and exhibits prognostic and therapeutic significance in non-small cell lung cancer 

Tarun Tyagi, PhD – Yale University

Session IX: Immuno-Metabolism and Immunotherapy Response

Co-Chairs:
Luke O’Neill, PhD – Trinity College Dublin
Jeffery Rathmell, PhD – Vanderbilt University Medical Center

T Cell Metabolism in the Context of Adoptive Immunotherapy for Cancer

Chrystal Paulos, PhD – Winship Cancer Institute at Emory University

(30) PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program

Masao Hashimoto, MD, PhD – Emory University

(74) Adrenergic receptor signaling regulates the CD40-receptor mediated anti-tumor

Akansha Singh, PhD – Oklahoma State University